What are the price targets for aptose Biosciences'stock?
5 brokers have issued 1 year price targets for Aptose Biosciences' stock. Their forecasts range from $7.00 to $14.00. On average, they anticipate Aptose Biosciences' stock price to reach $11.00 in the next year. This suggests a possible upside of 382.5% from the stock's current price.
Where can I buy shares of apto?
Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is aptose Biosciences (apto) in oversold territory?
Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es...
Will aptose Biosciences (apto) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote “Outperform” if you believe APTO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Is Apto stock a good buy?
Aptose Biosciences Inc (NASDAQ:APTO) The 7 analysts offering 12-month price forecasts for Aptose Biosciences Inc have a median target of 9.00, with a high estimate of 13.00 and a low estimate of 3.00. The median estimate represents a +1,001.73% increase from the last price of 0.82.
Is Aptose Biosciences stock a buy?
Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Why is Aptose Biosciences stock dropping?
The decline came after the company presented preliminary clinical data from an early-stage clinical study evaluating CG-806 in treating relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), or non-Hodgkin lymphoma (NHL).
About Aptose Biosciences
Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
5 Beaten-Down Biotech Bets to Bounce Back in 2022
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 5 buy ratings for the stock.
Aptose Shares Fall After Ceasing APTO-253 Program
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
Aptose Biosciences Inc (NASDAQ: APTO) will discontinue further clinical development of APTO-253 in hematologic malignancies and solid tumors. The decision follows the prioritization of the Company's ot...
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in patients relapsed or refractory acute myeloid leukemia (AML) who had received at least one prior line ...
Aptose to Hold Corporate Update Monday, December 13th
HM43 239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting
Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting Luxeptinib clinical update in AML and B-cell cancers
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
Investors need to pay close attention to Aptose Biosciences (APTO) stock based on the movements in the options market lately.
How long are futures trading delayed?
SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...
How to calculate restricted stock?
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.
What is market capitalization for companies?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Signals & Forecast
For companies with multiple common share classes, market capitalization includes both classes. Shares Outstanding. Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public. Public Float.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Is Aptose Biosciences stock A Buy?
Aptose Biosciences finds support from accumulated volume at $1.16 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Aptose Biosciences
Aptose Biosciences holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Aptose Biosciences
In the last 100 trades there were 11.7 million shares bought and 870.47 thousand shares sold. The last trade was done 37 days ago by Ashe Carol Gail who bough 50 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
